Covid Reference

Page 445

Severe COVID-19

|

445

Factors and characteristics to develop one type over the other have been identified: severity of the initial infection, the patient’s immune response, the patient’s physical fitness and comorbidities, the response of the hypoxemia to the ventilation, and the time between first symptoms and hospital admission (Gattinoni 2020). L type patients remain stable before improvement or deterioration. In the latter case the patients develop H type pneumonia (Pfeifer 2020). According to this theory, a ventilation strategy starting with respiratory support with high flow oxygen has been recommended (Gattinoni 2020). To adequately assess oxygenation, the oxygen content (CaO2) in the blood is helpul, as it describes the actual oxygen supply (DO2) better than the oxygen partial pressure (pO2), particularly when combined with the cardiac output (CO): DO2 = CaO2 x CO and CaO2 = Hb x SaO2 x 1.4 With a CaO2 limit of 10 g/100 ml blood, and an appropriate cardiac output, i.e., absence of cardiac failure, a lower O2 saturation (hypoxemia) can be tolerated in the blood before a critical oxygen shortage in the tissue (hypoxia) develops. Therefore, rather than strictly focusing on pO2 values as represented by the oxygenation index PaO2/FiO2 of < 150, it is more reasonable to consider the overall clinical picture while setting individual target values before intubation. Attempting high-flow oxygen and non-invasive ventilation in patients with type L pneumonia is recommended. Intubation should only be performed if there is significant clinical deterioration (Lyons 2020, Pfeifer 2020).

Special situations in severe COVID-19 Prone positioning Prone position (PP) has become a therapeutic option, even in awake, nonintubated patients, during spontaneous and assisted breathing (Telias 2020). In one study, among 50 patients, the median SpO2 at triage was 80%. After supplemental oxygen was given to patients on room air it was 84%. After 5 minutes of proning was added, SpO2 improved to 94% (Caputo 2020). Whether PP prevents intubation is not known yet. In a prospective before-after study in Aix-en-Provence, France among 24 awake, non-intubated, spontaneously breathing patients with COVID-19 and hypoxemic acute respiratory failure requiring oxygen supplementation, the effect of PP was only moderate. 63% were able to tolerate PP for more than 3 hours. Oxygenation increased in only 25% and was not sustained in half of

COVID Reference ENG 006.9


Turn static files into dynamic content formats.

Create a flipbook

Articles inside

References

1hr
pages 497-554

Management

10min
pages 491-496

Diagnosis and classification

11min
pages 484-490

Transplantation

4min
pages 472-473

Transmission

4min
pages 482-483

Pathophysiology and immunopathology

4min
pages 480-481

Natural course and risk factors for complications

2min
page 479

Epidemiology of COVID-19 in children

2min
page 478

Cancer

8min
pages 468-471

Immunosuppression (other than HIV

3min
pages 466-467

HIV infection

6min
pages 463-465

COPD and smoking

4min
pages 461-462

Hypertension and cardiovascular co-morbidities

14min
pages 452-458

Diabetes mellitus

4min
pages 459-460

References

6min
pages 447-451

Special situations in severe COVID-19

3min
pages 445-446

References

25min
pages 429-440

Spotlight: The situation in a German COVID-19 hospital

4min
pages 443-444

Outlook and Recommendations

1min
page 428

4. Immunomodulators

19min
pages 415-424

Other treatments for COVID-19 (with unknown or unproven mechanisms of action

5min
pages 425-427

3. Monoclonal Antibodies and Convalescent Plasma

13min
pages 408-414

2. Various antiviral agents

5min
pages 405-407

1. Inhibitors of the viral RNA synthesis

11min
pages 399-404

Monitoring, treatment options

3min
pages 391-392

Studies with objectifiable tests

3min
pages 389-390

Reactivations, reinfections

2min
page 366

Outcome

27min
pages 352-365

Clinical classification

1min
page 351

Laboratory findings

6min
pages 347-350

References

21min
pages 324-332

Asymptomatic cases

4min
pages 334-335

Radiology

6min
pages 321-323

Incubation period

1min
page 333

Symptoms

21min
pages 336-346

Diagnosis

36min
pages 303-320

References

55min
pages 277-302

Outlook

5min
pages 272-276

Single Vaccines

24min
pages 247-261

Coming vaccines

8min
pages 267-271

Special Topics

9min
pages 241-246

Approved Vaccines

2min
pages 223-224

References

21min
pages 211-222

Outlook

1min
page 210

Transmission

1min
page 187

Epidemiology

11min
pages 175-186

Summary – 13 February

1min
page 173

Genomic Structure and Variation

4min
pages 164-166

References

8min
pages 167-172

Origin and Evolution

4min
pages 158-159

Introduction

1min
page 174

History

4min
pages 154-155

References

20min
pages 136-152

Conclusion

1min
page 135

Introduction

31min
pages 117-133

Containment or mitigation of COVID-19?

1min
page 134

References

40min
pages 99-116

Outlook

1min
page 98

Prevention

3min
pages 96-97

End of Quarantine

1min
page 95

Transmission Event

26min
pages 82-94

References

31min
pages 54-68

Summary

1min
page 69

Routes of Transmission

16min
pages 73-81

Outlook

3min
pages 52-53

The 2020 Lockdowns

7min
pages 48-51

Person-to-person transmission

2min
page 72

Special Aspects of the Pandemic

15min
pages 38-46

The SARS-CoV-2 pandemic: Past and Future

2min
page 47
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.